10x Genomics (TXG) Non-Current Assets (2018 - 2026)

10x Genomics has disclosed Non-Current Assets across 9 years of filings, most recently posting $346.0 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $346.0 million, up 6.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 billion (up 3.14% YoY), and the FY2025 annual result was $356.9 million, up 6.78% from the prior year.
• Non-Current Assets came in at $346.0 million for Q1 2026 at 10x Genomics, down from $356.9 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $412.1 million in Q1 2023 to a low of $305.9 million in Q1 2022.
• The 5-year median for Non-Current Assets is $355.8 million (2024), against an average of $357.6 million.
• Across the five-year window, Non-Current Assets surged 52.16% in 2022 and fell 13.81% in 2024, its largest moves.
• 10x Genomics' Non-Current Assets stood at $393.9 million in 2022, then decreased by 6.3% to $369.1 million in 2023, then declined by 9.45% to $334.2 million in 2024, then rose by 6.78% to $356.9 million in 2025, then slipped by 3.05% to $346.0 million in 2026.
• The last three Non-Current Assets figures came in at $346.0 million (Q1 2026), $356.9 million (Q4 2025), and $367.5 million (Q3 2025), per Business Quant data.